卡氏肺孢子虫肺炎大鼠模型对持续输注去铁胺的反应。
Response of rat model of Pneumocystis carinii pneumonia to continuous infusion of deferoxamine.
作者信息
Merali S, Chin K, Grady R W, Weissberger L, Clarkson A B
机构信息
Department of Medical and Molecular Parasitology, New York University School of Medicine, New York 10016, USA.
出版信息
Antimicrob Agents Chemother. 1995 Jul;39(7):1442-4. doi: 10.1128/AAC.39.7.1442.
Abstract
The iron-chelating drug deferoxamine mesylate (DFO) is active against Pneumocystis carinii in vitro and in rat and mouse models of P. carinii pneumonia. Because DFO has a short half-life, daily divided or continuous dosage was expected to improve the dose response, as is the case with DFO treatment of malaria. Therefore, results of single daily intraperitoneal injections were compared with results of an evenly divided four-times-daily dosage and the efficacy of delivery with implanted infusion pumps. The highest bolus dosage (1,000 mg kg-1 of body weight day-1) was as effective as the standard combination of trimethoprim with sulfamethoxazole. Unexpectedly, very little improvement was observed with the divided or continuous dosage, and several mechanisms that could account for this are discussed.
摘要
铁螯合剂甲磺酸去铁胺（DFO）在体外以及卡氏肺孢子虫肺炎的大鼠和小鼠模型中对卡氏肺孢子虫具有活性。由于DFO半衰期短，预计每日分次给药或持续给药会改善剂量反应，就如同DFO治疗疟疾的情况一样。因此，将每日单次腹腔注射的结果与每日均匀分四次给药的结果以及植入式输液泵给药的疗效进行了比较。最高推注剂量（1000 mg·kg-1体重·日-1）与甲氧苄啶联合磺胺甲恶唑的标准组合效果相当。出乎意料的是，分次给药或持续给药几乎没有观察到改善，文中讨论了几种可能解释此现象的机制。
相似文献
1
Response of rat model of Pneumocystis carinii pneumonia to continuous infusion of deferoxamine.卡氏肺孢子虫肺炎大鼠模型对持续输注去铁胺的反应。
Antimicrob Agents Chemother. 1995 Jul;39(7):1442-4. doi: 10.1128/AAC.39.7.1442.
2
Action of deferoxamine against Pneumocystis carinii.去铁胺对卡氏肺孢子虫的作用。
Antimicrob Agents Chemother. 2001 Dec;45(12):3560-5. doi: 10.1128/AAC.45.12.3560-3565.2001.
3
Clinically achievable plasma deferoxamine concentrations are therapeutic in a rat model of Pneumocystis carinii pneumonia.在卡氏肺孢子虫肺炎大鼠模型中，临床可达到的去铁胺血浆浓度具有治疗作用。
Antimicrob Agents Chemother. 1995 Sep;39(9):2023-6. doi: 10.1128/AAC.39.9.2023.
4
Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia.去铁胺和依氟鸟氨酸（DL-α-二氟甲基鸟氨酸）在卡氏肺孢子虫肺炎大鼠模型中的应用
Antimicrob Agents Chemother. 1990 Sep;34(9):1833-5. doi: 10.1128/AAC.34.9.1833.
5
Continuous infusion of DL-alpha-difluoromethylornithine and improved efficacy against a rat model of Pneumocystis carinii pneumonia.持续输注DL-α-二氟甲基鸟氨酸可提高对卡氏肺孢子虫肺炎大鼠模型的疗效。
Antimicrob Agents Chemother. 1996 Oct;40(10):2318-20. doi: 10.1128/AAC.40.10.2318.
6
Trophozoite elimination in a rat model of Pneumocystis carinii pneumonia by clinically achievable plasma deferoxamine concentrations.在卡氏肺孢子虫肺炎大鼠模型中，通过临床可达到的血浆去铁胺浓度消除滋养体。
Antimicrob Agents Chemother. 1996 May;40(5):1298-300. doi: 10.1128/AAC.40.5.1298.
7
Iron chelators as therapeutic agents against Pneumocystis carinii.铁螯合剂作为抗卡氏肺孢子虫的治疗药物。
Antimicrob Agents Chemother. 1994 May;38(5):997-1003. doi: 10.1128/AAC.38.5.997.
8
Efficacy of intermittent dosage of 8-aminoquinolines for therapy or prophylaxis of Pneumocystis pneumonia in rats.间歇性给予8-氨基喹啉对大鼠肺孢子菌肺炎的治疗或预防效果。
J Infect Dis. 1992 Apr;165(4):764-8. doi: 10.1093/infdis/165.4.764.
9
Improved rat model of Pneumocystis carinii pneumonia: induced laboratory infections in Pneumocystis-free animals.卡氏肺孢子虫肺炎的改良大鼠模型：在无肺孢子虫动物中诱导实验室感染
Infect Immun. 1992 Apr;60(4):1589-97. doi: 10.1128/iai.60.4.1589-1597.1992.
10
Activity of terbinafine against Pneumocystis carinii in vitro and its efficacy in the treatment of experimental pneumonia.特比萘芬对卡氏肺孢子虫的体外活性及其在实验性肺炎治疗中的疗效。
J Antimicrob Chemother. 1994 Nov;34(5):727-35. doi: 10.1093/jac/34.5.727.
引用本文的文献
1
Action of deferoxamine against Pneumocystis carinii.去铁胺对卡氏肺孢子虫的作用。
Antimicrob Agents Chemother. 2001 Dec;45(12):3560-5. doi: 10.1128/AAC.45.12.3560-3565.2001.
2
Continuous axenic cultivation of Pneumocystis carinii.卡氏肺孢子虫的连续无菌培养
Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2402-7. doi: 10.1073/pnas.96.5.2402.
3
Continuous infusion of DL-alpha-difluoromethylornithine and improved efficacy against a rat model of Pneumocystis carinii pneumonia.持续输注DL-α-二氟甲基鸟氨酸可提高对卡氏肺孢子虫肺炎大鼠模型的疗效。
Antimicrob Agents Chemother. 1996 Oct;40(10):2318-20. doi: 10.1128/AAC.40.10.2318.
4
Polyamine content of Pneumocystis carinii and response to the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine.卡氏肺孢子虫的多胺含量及对鸟氨酸脱羧酶抑制剂DL-α-二氟甲基鸟氨酸的反应
Antimicrob Agents Chemother. 1996 Apr;40(4):973-8. doi: 10.1128/AAC.40.4.973.
5
Trophozoite elimination in a rat model of Pneumocystis carinii pneumonia by clinically achievable plasma deferoxamine concentrations.在卡氏肺孢子虫肺炎大鼠模型中，通过临床可达到的血浆去铁胺浓度消除滋养体。
Antimicrob Agents Chemother. 1996 May;40(5):1298-300. doi: 10.1128/AAC.40.5.1298.
6
Clinically achievable plasma deferoxamine concentrations are therapeutic in a rat model of Pneumocystis carinii pneumonia.在卡氏肺孢子虫肺炎大鼠模型中，临床可达到的去铁胺血浆浓度具有治疗作用。
Antimicrob Agents Chemother. 1995 Sep;39(9):2023-6. doi: 10.1128/AAC.39.9.2023.
本文引用的文献
1
Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients.
Drug Metab Dispos. 1993 Jul-Aug;21(4):640-4.
2
Iron chelators as therapeutic agents against Pneumocystis carinii.铁螯合剂作为抗卡氏肺孢子虫的治疗药物。
Antimicrob Agents Chemother. 1994 May;38(5):997-1003. doi: 10.1128/AAC.38.5.997.
3
Iron chelation therapy for malaria.用于疟疾的铁螯合疗法。
Adv Exp Med Biol. 1994;356:371-83. doi: 10.1007/978-1-4615-2554-7_39.
4
Ornithine decarboxylase in Pneumocystis carinii and implications for therapy.卡氏肺孢子虫中的鸟氨酸脱羧酶及其治疗意义。
Antimicrob Agents Chemother. 1994 Nov;38(11):2545-52. doi: 10.1128/AAC.38.11.2545.
5
Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies.卡氏肺孢子虫肺炎：获得性免疫缺陷综合征患者与其他免疫缺陷患者的比较。
Ann Intern Med. 1984 May;100(5):663-71. doi: 10.7326/0003-4819-100-5-663.
6
Effect of desferrioxamine on removal of aluminum and iron by coated charcoal haemoperfusion and haemodialysis.去铁胺对包膜活性炭血液灌流和血液透析清除铝和铁的影响。
Lancet. 1983 Nov 5;2(8358):1051-3. doi: 10.1016/s0140-6736(83)91039-5.
7
The metabolism of desferrioxamine B and ferrioxamine B.去铁胺B和铁胺B的代谢
Biochem Pharmacol. 1967 Mar;16(3):527-35. doi: 10.1016/0006-2952(67)90100-1.
8
Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis.去铁胺和铁胺在健康受试者及血色素沉着症患者中的药代动力学及肾脏清除情况。
Br J Clin Pharmacol. 1987 Aug;24(2):207-12. doi: 10.1111/j.1365-2125.1987.tb03163.x.
9
Desferrioxamine suppresses Plasmodium falciparum in Aotus monkeys.去铁胺可抑制夜猴体内的恶性疟原虫。
Proc Soc Exp Biol Med. 1987 Feb;184(2):162-4. doi: 10.3181/00379727-184-42461.
10
Pharmacokinetics of desferrioxamine and of its iron and aluminium chelates in patients on haemodialysis.
Clin Chim Acta. 1987 Dec;170(2-3):331-8. doi: 10.1016/0009-8981(87)90144-6.
Zotero 插件